UPCC 01622 Neoadjuvant PD-1 blockade in resectable Merkel cell carcinoma
Age
99 years or below
Gender
All
participants needed
15
Location
1
Brief description of study
Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please reer to Protocol Section 3.2 (Secondary Objective(s), Hypothesis(es), and Endpoint(s)
Eligibility of study
You may be eligible for this study if you meet the following criteria: